Kyung Taek Oh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kyung Taek Oh has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Kevin J. Clerkin
Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032
4 shared publications - David T. Majure
Division of Cardiology, Department of Medicine. Weill Cornell Medical Center, New York, NY
3 shared publications - Dor Lotan
Center for Pericardial Diseases, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York-Presbyterian Hospital, New York, NY, USA
3 shared publications - Ersilia M. DeFilippis
Center for Advanced Cardiac Care, Division of Cardiology, Columbia University Irving Medical Center, New York, New York, USA
3 shared publications - Gabriel Sayer
Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York
3 shared publications - Nir Uriel
Columbia University Irving Medical Center
3 shared publications
Latest Publications
- 18 July 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (12) , 1886-1895
Out of sequence heart transplants: Why, how many, and to whom
- 18 July 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (12) , 1886-1895
Out of sequence heart transplants: Why, how many, and to whom
- 28 May 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (10) , 1612-1620
Efficacy and safety of belatacept in heart transplant recipients
- 28 May 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (10) , 1612-1620
Efficacy and safety of belatacept in heart transplant recipients
- 1 January 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (1) , e011756
Elevated Donor-Derived Cell-Free DNA Levels Are Associated With Reduced Myocardial Blood Flow but Not Angiographic Cardiac Allograft Vasculopathy: The EVIDENT Study
BACKGROUND: Cardiac allograft vasculopathy (CAV) leads to impaired myocardial blood flow (MBF), increasing the risk of cardiovascular death or retransplant among heart transplantation (HT) recipients. Data on elevation in donor-derived cell-free DNA (dd-cfDNA) and CAV in the absence of rejection are mixed. We sought to test the hypothesis that CAV with reduced MBF (RMBF) is associated with elevated dd-cfDNA. METHODS: A retrospective review was conducted on HT recipients at a high-volume center who underwent dd-cfDNA testing between September 2019 and November 2022. Inclusion criteria included undergoing CAV screening with cardiac positron emission tomography scans and coronary angiograms. Patients were grouped by the presence of angiographic CAV diagnosis and MBF reserve evaluated through cardiac positron emission tomography. The latter was subdivided into normal MBF or RMBF, with RMBF defined as an MBF reserve ≤2. Elevated dd-cfDNA was defined as ≥0.12%. RESULTS: Two hundred fifty-six HT recipients were included (median age, 55 years; 27.6% female; median, 8 years [interquartile range (IQR), 5–14] post-HT). Ischemic etiology of heart failure was more prevalent in the RMBF group (36%) compared with the normal MBF group (20%; P =0.02). The prevalence and magnitude of a positive dd-cfDNA test with angiographic CAV (29%; median, 0.26% [IQR, 0.15%–0.62%]) were not significantly different from those without CAV (30%; P =0.94; median, 0.31% [IQR, 0.17%–0.71%]; P =0.38). However, RMBF patients exhibited significantly higher dd-cfDNA prevalence and levels (51%; median, 0.81% [IQR, 0.48%–1.11%]) compared with normal MBF patients (27%; P P <0.001). CONCLUSIONS: HT recipients with angiographic CAV had similar dd-cfDNA levels and rates as those without. Notably, dd-cfDNA levels and rates were significantly elevated in patients with RMBF assessed by positron emission tomography compared with those with normal MBF.
- 1 January 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (1) , e011756
Elevated Donor-Derived Cell-Free DNA Levels Are Associated With Reduced Myocardial Blood Flow but Not Angiographic Cardiac Allograft Vasculopathy: The EVIDENT Study
BACKGROUND: Cardiac allograft vasculopathy (CAV) leads to impaired myocardial blood flow (MBF), increasing the risk of cardiovascular death or retransplant among heart transplantation (HT) recipients. Data on elevation in donor-derived cell-free DNA (dd-cfDNA) and CAV in the absence of rejection are mixed. We sought to test the hypothesis that CAV with reduced MBF (RMBF) is associated with elevated dd-cfDNA. METHODS: A retrospective review was conducted on HT recipients at a high-volume center who underwent dd-cfDNA testing between September 2019 and November 2022. Inclusion criteria included undergoing CAV screening with cardiac positron emission tomography scans and coronary angiograms. Patients were grouped by the presence of angiographic CAV diagnosis and MBF reserve evaluated through cardiac positron emission tomography. The latter was subdivided into normal MBF or RMBF, with RMBF defined as an MBF reserve ≤2. Elevated dd-cfDNA was defined as ≥0.12%. RESULTS: Two hundred fifty-six HT recipients were included (median age, 55 years; 27.6% female; median, 8 years [interquartile range (IQR), 5–14] post-HT). Ischemic etiology of heart failure was more prevalent in the RMBF group (36%) compared with the normal MBF group (20%; P =0.02). The prevalence and magnitude of a positive dd-cfDNA test with angiographic CAV (29%; median, 0.26% [IQR, 0.15%–0.62%]) were not significantly different from those without CAV (30%; P =0.94; median, 0.31% [IQR, 0.17%–0.71%]; P =0.38). However, RMBF patients exhibited significantly higher dd-cfDNA prevalence and levels (51%; median, 0.81% [IQR, 0.48%–1.11%]) compared with normal MBF patients (27%; P P <0.001). CONCLUSIONS: HT recipients with angiographic CAV had similar dd-cfDNA levels and rates as those without. Notably, dd-cfDNA levels and rates were significantly elevated in patients with RMBF assessed by positron emission tomography compared with those with normal MBF.
- 1 October 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (8) , 2626-2629
A Rare Case of Disseminated Tuberculosis and Hematological Malignancy in a Heart Transplant Recipient
- 1 October 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (8) , 2626-2629
A Rare Case of Disseminated Tuberculosis and Hematological Malignancy in a Heart Transplant Recipient
- Open Access
- 8 June 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (2) , 825-829
Protocol endomyocardial biopsy beyond 6 months—It is time to move on
- 8 June 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (2) , 825-829
Open AccessProtocol endomyocardial biopsy beyond 6 months—It is time to move on